ArticleTranslational oncology2026
Telomerase-related gene EHHADH drives lung cancer progression and shapes the immunosuppressive tumor microenvironment.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a leading cause of cancer-related mortality, necessitating accurate prognostic assessment and optimized treatment. Telomerase-related genes are pivotal in tumor development, yet their prognostic value and mechanisms within the lung cancer tumor microenvironment (TME) remain unclear.
methodsWe analyzed telomerase-related gene mutations in lung cancer (TCGA) and identified eight key prognostic genes (INMT, ALDH3A2, OGDHL, TDO2, EFNA3, STAT1, EHHADH, AANAT) from seven public datasets via Cox regression. A robust prognostic risk model was built and validated across independent cohorts. TME associations were explored using IPS, ESTIMATE scores, and immune infiltration analyses. EHHADH's functional role was validated via immunohistochemistry, in vitro knockdown, and single-cell RNA sequencing.
resultsOur model demonstrated strong predictive performance and consistently outperformed existing prognostic signatures across multiple datasets. Importantly, low-risk patients exhibited an "immune-hot" phenotype with higher IPS scores and enhanced immune cell infiltration, suggesting potential sensitivity to immunotherapy. In contrast, high-risk patients displayed an immunosuppressive microenvironment. Among the model genes, EHHADH emerged as a key oncogenic driver, positively associated with risk score and poor survival. Functional assays revealed that EHHADH promotes tumor cell migration while reducing adhesion. Single-cell analysis further demonstrated that EHHADH is predominantly expressed in epithelial cells and is associated with an "immune-desert" TME characterized by reduced immune infiltration.
conclusionThis study establishes a clinically relevant telomerase-related gene signature that enables effective risk stratification and provides insights into tumor-immune interactions in lung cancer. Notably, EHHADH is identified as a potential therapeutic target that contributes to immune evasion and tumor progression. These findings offer a foundation for personalized prognostic assessment and suggest that targeting EHHADH may enhance the efficacy of immunotherapy in lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.